Effects of psychological stress and fluoxetine on development of oral candidiasis in rats.
Psychological stress has been found to suppress cell-mediated immune responses that are important for limiting the proliferation of Candida albicans. Fluoxetine has been observed to reduce negative consequences of stress on the immune system in experimental and clinical models, but there are no data on its effects on oral candidiasis. We designed experiments to evaluate the effects of fluoxetine on the development of oral candidiasis in Sprague-Dawley rats exposed to a chronic auditory stressor. Animals were submitted to surgical hyposalivation in order to facilitate the establishment and persistence of C. albicans infection. Stress application and treatment with drugs (placebo or fluoxetine) were initiated 7 days before C. albicans inoculation and lasted until the end of the experiments, on day 15 postinoculation. Establishment of C. albicans infection was evaluated on days 2 and 15 after inoculation. Tissue injury was determined by the quantification of the number and type (normal or abnormal) of papillae on the dorsal tongue per microscopic field. A semiquantitative scale was devised to assess the degree of colonization of the epithelium by fungal hyphae. Our results showed that stress exacerbates C. albicans infection in the tongues of rats. Significant increases in Candida counts, the percentage of the tongue's surface covered with clinical lesions, the percentage of abnormal papillae, and the colonization of the epithelium by hyphae were found in stressed rats compared to the nonstressed ones. Treatment with fluoxetine significantly reversed these adverse effects of stress. Besides the psychopharmacological properties of fluoxetine against stress, it has consequences for Candida infection.
Núñez
María J
MJ
Neuroimmunology Laboratory, Department of Pharmacology, School of Medicine, San Francisco, 15782 Santiago de Compostela, A Coruña, Spain.
Novío
Silvia
S
Suárez
Juan Antonio
JA
Balboa
José
J
Freire-Garabal
Manuel
M
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002176:Candida albicans / Q000302:isolation & purification*; D002180:Candidiasis, Oral / Q000382:microbiology / Q000517:prevention & control*; D015169:Colony Count, Microbial; D005473:Fluoxetine / Q000627:therapeutic use*; D009061:Mouth Mucosa / Q000473:pathology; D010919:Placebos / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D013315:Stress, Psychological / Q000150:complications* / Q000188:drug therapy*; D014059:Tongue / Q000473:pathology
D018687:Antidepressive Agents, Second-Generation; D010919:Placebos; D005473:Fluoxetine